| scholarly article | Q13442814 |
| P50 | author | Iain McInnes | Q41687181 |
| Christopher T Ritchlin | Q80623665 | ||
| Arthur Kavanaugh | Q93106996 | ||
| P2093 | author name string | Shu Li | |
| Yuhua Wang | |||
| Proton Rahman | |||
| Alan M Mendelsohn | |||
| Alice B Gottlieb | |||
| Lluis Puig | |||
| Mittie K Doyle | |||
| Yaung-Kaung Shen | |||
| PSUMMIT 2 Study Group | |||
| P2860 | cites work | The MOS 36-ltem Short-Form Health Survey (SF-36) | Q26778425 |
| Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis | Q28270369 | ||
| Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) | Q28280453 | ||
| Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) | Q28280465 | ||
| A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index | Q28299001 | ||
| Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study | Q30612910 | ||
| Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, pla | Q30760660 | ||
| Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations | Q33369384 | ||
| Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis | Q34315745 | ||
| Severe Psoriasis – Oral Therapy with a New Retinoid | Q34690752 | ||
| Assessment of enthesitis in ankylosing spondylitis | Q35552370 | ||
| Psoriatic arthritis: epidemiology, clinical features, course, and outcome | Q35579437 | ||
| ASAS/EULAR recommendations for the management of ankylosing spondylitis | Q35637012 | ||
| From skin to bone: translational perspectives on psoriatic disease | Q37210197 | ||
| Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. | Q37935050 | ||
| To switch or not to switch after a poor response to a TNFα blocker? It is not only a matter of ACR20 OR ACR50. | Q37950781 | ||
| Ustekinumab in clinical practice: response depends on dose and previous treatment | Q37955295 | ||
| Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis. | Q38099408 | ||
| Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. | Q42495512 | ||
| Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients | Q44300565 | ||
| Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. | Q45962385 | ||
| Comorbidities of psoriatic arthritis -- metabolic syndrome and prevention: a report from the GRAPPA 2010 annual meeting | Q46438860 | ||
| Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry | Q46893265 | ||
| American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis | Q47643186 | ||
| Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohorts | Q48920916 | ||
| Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. | Q50882370 | ||
| Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. | Q50906224 | ||
| Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. | Q51821980 | ||
| Measurement of patient outcome in arthritis | Q56879288 | ||
| Mortality studies in psoriatic arthritis. Results from a single outpatient clinic. I. Causes and risk of death | Q60700017 | ||
| Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on e | Q63101754 | ||
| Comparison of disability and quality of life in rheumatoid and psoriatic arthritis | Q74385099 | ||
| Classification criteria for psoriatic arthritis: development of new criteria from a large international study | Q80001900 | ||
| Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis | Q81710047 | ||
| A 3 mg/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs | Q84582430 | ||
| Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up | Q85858615 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| patient | Q181600 | ||
| monoclonal antibody | Q422248 | ||
| psoriatic arthritis | Q511097 | ||
| TNF | Q18032037 | ||
| P304 | page(s) | 990-999 | |
| P577 | publication date | 2014-01-30 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas | |
| P478 | volume | 73 |
| Q90664422 | A Review for Physician Assistants and Nurse Practitioners on the Considerations for Diagnosing and Treating Psoriatic Arthritis |
| Q90415213 | A new player in psoriatic arthritis: a JAK inhibitor |
| Q38236514 | A review of disease activity measures for psoriatic arthritis: what is the best approach? |
| Q38749257 | A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases |
| Q56891106 | Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives |
| Q99547421 | Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review |
| Q27001017 | Advances in the treatment of polyarticular juvenile idiopathic arthritis |
| Q47734526 | Altered Bone Remodeling in Psoriatic Disease: New Insights and Future Directions |
| Q38445764 | Altered immunoregulation in rheumatoid arthritis: the role of regulatory T cells and proinflammatory Th17 cells and therapeutic implications |
| Q99238557 | An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis |
| Q47727612 | Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions |
| Q38616811 | Apremilast for the treatment of psoriatic arthritis |
| Q55109332 | Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic review. |
| Q38845301 | Autoinflammation and HLA-B27: Beyond Antigen Presentation |
| Q55117680 | Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. |
| Q92410206 | Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia |
| Q38766379 | Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis |
| Q89608770 | Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial |
| Q38866152 | Biologics in Pediatric Rheumatology: Quo Vadis? |
| Q26746100 | Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials |
| Q64921248 | Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative. |
| Q92422137 | Cartilage and Bone Destruction in Arthritis: Pathogenesis and Treatment Strategy: A Literature Review |
| Q38344194 | Certolizumab pegol for the treatment of psoriatic arthritis |
| Q64231010 | Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review |
| Q89074054 | Clinical management of psoriatic arthritis |
| Q38648826 | Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison |
| Q26764820 | Comparative Effectiveness of Biologic Therapy Regimens for Ankylosing Spondylitis: A Systematic Review and a Network Meta-Analysis |
| Q47236145 | Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis. |
| Q50002313 | Consensus on the management of patients with psoriatic arthritis in a dermatology setting |
| Q38553845 | Contribution of the IL-17 Pathway to Psoriasis and Psoriatic Arthritis |
| Q52664758 | Cytokines in uveitis. |
| Q38540408 | Diagnosis and Management of Late-Onset Spondyloarthritis: Implications of Treat-to-Target Recommendations |
| Q38998373 | Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis |
| Q38759376 | Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options |
| Q48093013 | Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE). |
| Q37352347 | Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). |
| Q36182389 | Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure |
| Q47230622 | Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study |
| Q91860943 | Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis |
| Q90630025 | Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials |
| Q41449533 | Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis |
| Q89865617 | Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis |
| Q49824739 | Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis |
| Q40437510 | Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: Results of the SPREAD study |
| Q89074034 | Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study |
| Q40705952 | Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). |
| Q58570651 | Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies |
| Q38202538 | Efficacy of tocilizumab in a patient with refractory psoriatic arthritis |
| Q90355990 | Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2 |
| Q38710642 | Emerging drugs for psoriatic arthritis |
| Q38313266 | Emerging drugs for the treatment of axial and peripheral spondyloarthritis |
| Q90232146 | Enthesitis in psoriatic arthritis (Part 3): clinical assessment and management |
| Q55119878 | Enthesitis: Much More Than Focal Insertion Point Inflammation. |
| Q38661777 | European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update |
| Q61812079 | Evolution of psoriatic arthritis study patient population characteristics in the era of biological treatments |
| Q38838470 | Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region. |
| Q92771511 | Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis |
| Q98210385 | Fourteen small molecule and biological agents for psoriatic arthritis: A network meta-analysis of randomized controlled trials |
| Q38794862 | Fungal Infections and New Biologic Therapies |
| Q61815863 | Human leukocyte antigen and demographic characteristics in Chinese patients with active peripheral type psoriatic arthritis who had inadequate response to conventional disease-modifying antirheumatic drugs in a single dermatologic clinic |
| Q61651896 | IL-17 in the immunopathogenesis of spondyloarthritis |
| Q38255855 | IL-17RA in intestinal inflammation: structure, signaling, function, and clinical application |
| Q38421287 | IL-23 responsive innate-like T cells in spondyloarthritis: the less frequent they are, the more vital they appear. |
| Q38807623 | IL-23/IL-17 axis in spondyloarthritis-bench to bedside |
| Q91645587 | IL-7 is a Key Driver Cytokine in Spondyloarthritis? |
| Q59790838 | Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial |
| Q38725225 | Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis |
| Q57067878 | Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease |
| Q52836676 | Interleukin-17 inhibition in psoriatic arthritis. |
| Q42094104 | Involvement of the IL-23/IL-17 axis and the Th17/Treg balance in the pathogenesis and control of autoimmune arthritis |
| Q26783506 | Making the next steps in psoriatic arthritis management: current status and future directions |
| Q39004045 | Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations |
| Q92856727 | Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis |
| Q88205381 | Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study |
| Q37713522 | Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis |
| Q92464630 | Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis |
| Q48297584 | New onset or transition of disease state of psoriatic arthritis during treatment with ustekinumab: A single-center retrospective study. |
| Q28069592 | New targets in psoriatic arthritis |
| Q38266252 | New treatments for inflammatory rheumatic disease |
| Q47141159 | Next generation of biologics for the treatment of Crohn's disease: an evidence-based review on ustekinumab. |
| Q90734771 | Novel Diagnostic and Therapeutic Strategies in Juvenile Autoimmune Hepatitis |
| Q54977688 | Novel Therapeutics in Psoriatic Arthritis. What Is in the Pipeline? |
| Q38634276 | Novel approaches to biological therapy for psoriatic arthritis |
| Q38570721 | Novel treatment options for juvenile idiopathic arthritis |
| Q37345488 | Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study |
| Q41146632 | Peripheral Ulcerative Keratitis Associated with Autoimmune Disease: Pathogenesis and Treatment. |
| Q37460263 | Pharmacologic modulation of RORγt translates to efficacy in preclinical and translational models of psoriasis and inflammatory arthritis |
| Q38527552 | Pharmacological therapy of spondyloarthritis |
| Q38667430 | Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis |
| Q38630548 | Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis. |
| Q38230695 | Proteomics focusing on immune markers in psoriatic arthritis. |
| Q26744032 | Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same? |
| Q92127466 | Psoriatic Arthritis: What is Happening at the Joint? |
| Q90470107 | Psoriatic arthritis |
| Q38705872 | Psoriatic arthritis in 2015: Advancement continues in imaging, tight control and new drugs |
| Q51656945 | Psoriatic arthritis. |
| Q38542095 | Psoriatic arthritis: latest treatments and their place in therapy |
| Q89074002 | Psoriatic arthritis: novel targets add to a therapeutic renaissance |
| Q38978414 | Real-world effectiveness of anti-TNF switching in psoriatic arthritis: a systematic review of the literature |
| Q98386269 | Recurrent granulomatous cheilitis associated with Crohn's disease successfully treated with ustekinumab: case report and literature review |
| Q53733372 | Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis. |
| Q30399745 | Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders |
| Q38555291 | Review: animal models as a tool to dissect pivotal pathways driving spondyloarthritis. |
| Q97530140 | Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis |
| Q38357554 | Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges |
| Q33809045 | Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics |
| Q52608145 | Role of Methotrexate in the Management of Psoriatic Arthritis. |
| Q50099588 | Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints |
| Q38961129 | Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis |
| Q26798209 | Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory Myopathies |
| Q50214755 | Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab |
| Q38989105 | Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial |
| Q37138974 | Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity |
| Q91677820 | Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics |
| Q64229191 | Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials |
| Q46129663 | Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis. |
| Q47114261 | Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence |
| Q48166630 | Switching of biologics in psoriasis: Reasons and results |
| Q38693137 | T Helper 17 Cells in Primary Sjögren's Syndrome |
| Q92058308 | TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management |
| Q26764867 | Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies |
| Q47140713 | Targeting IL-17 in psoriatic arthritis |
| Q93246335 | Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis |
| Q38664951 | Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis |
| Q30235002 | The Changing Face of Clinical Trials in Psoriatic Arthritis |
| Q30383929 | The Clinical and Cost Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis: A Critique of the Evidence. |
| Q38879975 | The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy? |
| Q90430023 | The Initiation, but Not the Persistence, of Experimental Spondyloarthritis Is Dependent on Interleukin-23 Signaling |
| Q58567074 | The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future |
| Q58794936 | The localisation of the heparin binding sites of human and murine interleukin-12 within the carboxyterminal domain of the P40 subunit |
| Q98460557 | The risk of respiratory tract infections and interstitial lung disease with IL-12/23 and IL-23 antagonists in patients with autoimmune diseases: a systematic review and meta-analysis |
| Q38976762 | The role of IL 23 in the treatment of psoriasis |
| Q39328684 | The role of IL-12/23 in T cell-related chronic inflammation: implications of immunodeficiency and therapeutic blockade |
| Q39293096 | The role of IL-17 in the treatment of psoriatic arthritis |
| Q91664106 | The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies |
| Q48283709 | The role of IL-23 receptor signaling in inflammation-mediated erosive autoimmune arthritis and bone remodeling |
| Q38820480 | The safety of ustekinumab for the treatment of psoriatic arthritis |
| Q41067913 | Therapeutic Effects of Methanol Extract from Euphorbia kansui Radix on Imiquimod-Induced Psoriasis. |
| Q38543052 | Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases |
| Q39015080 | Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders. |
| Q59125383 | Therapies in ankylosing spondylitis-from clinical trials to clinical practice |
| Q87307785 | Therapy: Ustekinumab after anti-TNF failure: a step closer to the PSUMMIT of psoriatic arthritis therapy? |
| Q39003610 | Treatment of psoriatic arthritis with traditional DMARD's and novel therapies: approaches and recommendations. |
| Q51342040 | Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice. |
| Q96953884 | Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors |
| Q38685543 | Tumor necrosis factor inhibitors in psoriatic arthritis. |
| Q38264660 | Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity |
| Q46941311 | Unique topics and issues in rheumatology and clinical immunology |
| Q48287506 | Unmet Needs in Axial Spondyloarthritis |
| Q38900071 | Updates in Pediatric Rheumatology |
| Q34377347 | Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2014 MauiDerm Meeting |
| Q41813468 | Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic Arthritis |
| Q26771890 | Ustekinumab for the treatment of Crohn's disease: can it find its niche? |
| Q34154247 | Ustekinumab for the treatment of psoriatic arthritis: an update |
| Q91828617 | Ustekinumab in psoriatic arthritis and related phenotypes |
| Q36942960 | Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis |
| Q28067631 | Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy |
| Q30760660 | Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, pla |
| Q86162712 | Ustekinumab: The "New Kid on the Block" in the Treatment of Psoriatic Arthritis |
| Q38219591 | Ustekinumab: a review of its use in psoriatic arthritis |
| Q41591385 | WITHDRAWN: Experience with ustekinumab in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). |
| Q92737085 | What does evidence-based medicine tell us about treatments for different subtypes of psoriatic arthritis? A systematic literature review on randomized controlled trials |
| Q26778261 | What makes psoriatic and rheumatoid arthritis so different? |
| Q90267256 | When IL-17 inhibitors fail: Real-life evidence to switch from secukinumab to adalimumab or ustekinumab |
| Q55339808 | Whodunit? The Contribution of Interleukin (IL)-17/IL-22-Producing γδ T Cells, αβ T Cells, and Innate Lymphoid Cells to the Pathogenesis of Spondyloarthritis. |
| Q57293183 | Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation? |
| Q88420740 | [Psoriatic arthritis : Current therapeutic standards] |
| Q90442686 | [Treatment of psoriatic arthritis : Are there differential indications?] |
Search more.